17th World ADC San Diego | October 12-15, 2026

The preliminary agenda has just been released!

Returning as the largest and definitive ADC congress, the 17th World ADC San Diego is THE one-stop bioconjugate shop, bringing together the global ADC community for an unparalleled amalgamation of case studies, development trends, and networking opportunities to forge ADC innovation into differentiated, early-line patient outcomes.

With 7 streams of end-to-end ADC content across Discovery Chemistry, Discovery Biology, Preclinical, Translational Medicine, Clinical Lessons, Process & Analytical Development, and Manufacturing & Supply, all ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and push ADCs into earlier-line oncology treatments.

Download the preliminary agenda to explore the full program by stream. https://ter.li/y19qemt6

Uniting 1,300 senior industry enthusiasts from biopharma, innovative start-ups, leading service providers, and academic, physician, and regulatory KOLs, World ADC San Diego is the place to be to discuss, debate, and advance the future of ADC development.

New Industry-Leading Insights in 2026

Center Stage MoA, Targeting & Design Innovation to Advance Differentiated & Impactful ADC Therapies
Committed to holding the standard at the forefront of ADC research and development, the 2026 program has been infused with novel cytotoxic MoA, AOCs, DACs, ISACs, bsADCs, dpADCs, and conditionally active ADC discovery and translational insights.

Increasing Forum of Choice for Exclusive, First-Time ADC Data & Research Disclosures
PROTAC ADCs: Incorporating Historical Learnings to Navigate Novel Payload Development Beyond Blind Potency | AstraZeneca

Brand New Companies Making Their World ADC Debut
Committed to spotlighting continually refreshed and alternative perspectives on ADC development, hear from first-time presenting companies Callio Therapeutics, Canwell Pharma, Immunome, MediLink Therapeutics, NEOK Bio, Solve Therapeutics, and XYone Therapeutics.

Upgraded Clinical Content to Unlock ADC Differentiation
Evaluating I-SPY2 Clinical Data & Toxicity Monitoring to Assess ADC Progression to Early-Stage Oncology Settings in TNBC & HER2+ Breast Cancer | University of Chicago

View and download the preliminary agenda here to start building your personalized World ADC San Diego experience. https://ter.li/y19qemt6 
*Full program coming in June!